Nurix Therapeutics will present updated Phase 1a/1b efficacy and safety data on oral BTK degrader bexobrutideg in relapsed/refractory CLL/SLL at ASH 2026. The u

Nurix Therapeutics will present updated Phase 1a/1b efficacy and safety data on oral BTK degrader bexobrutideg in relapsed/refractory CLL/SLL at ASH 2026. The update follows recent program progress and first-patient dosing with Roche in a Phase 1b/2 CLL trial.